Press release
May 22, 2015

Heptares Scientist Wins Outstanding Young Chemist Award

London, UK and Boston, MA, USA, 22 May 2015 – Heptares Therapeutics is delighted to announce that Dr Steve Andrews, a Principal Scientist in its Medicinal Chemistry group, has been awarded the prestigious EFMC Prize for a Young Medicinal Chemist in Industry. The prize, awarded annually by The European Federation for Medicinal Chemistry (EFMC), acknowledges and recognises an outstanding young medicinal chemist (<10 years after PhD) working in industry within Europe. Dr Andrews will present aspects of his pioneering scientific work at the 6th EFMC International Symposium on Advances in Synthetic & Medicinal Chemistry (Rehovot, Israel, 15-18 November 2015).

Dr Andrews joined Heptares in 2008 as one of its first scientists. He has since been focused on developing and applying Heptares’ structure-based design platform to drug discovery for ‘intractable’ GPCRs (G protein-coupled receptors) and has developed novel compounds that bind to and modulate a range of receptors. Dr Andrews co-invented Heptares’ first clinical candidate, a selective adenosine A2A receptor antagonist, which became the first published example of structure-based design with GPCR X-ray structure (refs 1,2). Dr Andrews obtained his PhD from Cambridge University and undertook his post-doctoral studies at ETH-Zürich.

Malcolm Weir, Heptares CEO, said: “We congratulate Dr Andrews on this well-deserved commendation. This distinguished prize reinforces and reaffirms the scope of talent and excellence we have working within Heptares; just earlier in the year several Heptares scientists received The Malcolm Campbell Memorial Prize in recognition of their outstanding contribution to GPCR drug discovery. We are the industry pioneer in terms of our work in GPCR-guided structure-based drug design, and are proud to have nurtured such a dynamic and innovative team.”


  1. Identification of novel adenosine A2A receptor antagonists by virtual screening. Langmead CJ, et al. J Med Chem. 2012 Mar 8;55(5):1904-1909
  2. Discovery of 1,2,4-triazine derivatives as adenosine A2A antagonists using structure based drug design. Congreve M, et al. J Med Chem. 2012 Mar 8;55(5):1898-1903